Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s strategic progress and outlook for 2026, following a €4 million non-dilutive grant awarded by the Wallonia region. Dr Leire explained that the secured funding is part of Genflow’s broader capital efficiency strategy, helping the company focus on key pipeline catalysts, including its lead gene therapy, GF-1002.
GF-1002 is targeted at MASH (Metabolic dysfunction-associated steatohepatitis), a field Dr Leire described as “a huge unmet need,” particularly at the late stage where there are currently no therapeutic options. “This is one of the key programs for 2026,” he said, highlighting that GF-1002 addresses severe liver conditions, including hepatocellular carcinoma.
In addition to its gene therapy program, Genflow is advancing a pioneering longevity study in dogs. Leire stated, “A study on aged dogs, naive to therapies, that's blinded, randomised, so with very strong scientific standard will be a first in terms of longevity.” He emphasised the potential for a commercial deal with animal health companies based on this unique dataset.
Partnerships and capital efficiency remain central to Genflow’s plans. Leire noted that monetising non-core programs, such as the dog study, can generate significant non-dilutive capital and allow the company to focus on areas where it adds the most value.
Visit Proactive’s YouTube channel for more insightful videos like this one. Don’t forget to like the video, subscribe to the channel, and enable notifications for future updates.
#GenflowBiosciences #GeneTherapy #MASH #LongevityResearch #BiotechInvesting #GF1002 #NonDilutiveFunding #AnimalHealth #BiotechNews #2026Catalysts #GlaucomaResearch #CapitalEfficiency #LifeSciences #HealthcareInnovation #ProactiveInvestors
